Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Şirin, Fevzıye Burcu; Doğuç, Duygu Kumbul; Vural, Hüseyín; Eren, İbrahim; İnanlı, İkbal; Sütçü, Recep; Delibas, Namik

doi:10.3906/sag-1406-134

Cited by 32 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mild cognitive impairment and AD are frequently associated with low melatonin circulating concentrations in animal models [ 193 ]. With regard to clinical trials involving melatonin administration to humans, recent studies support the efficacy of melatonin in improving cognitive deterioration and reducing the so-called “sundown” effect [ 194 ].…”

Section: Melatonin Effects In Neuronal Inflammation and Degeneratimentioning

confidence: 99%

Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease

et al. 2020

View full text Add to dashboard Cite

There is a growing consensus that the antioxidant and anti-inflammatory properties of melatonin are of great importance in preserving the body functions and homeostasis, with great impact in the peripartum period and adult life. Melatonin promotes adaptation through allostasis and stands out as an endogenous, dietary, and therapeutic molecule with important health benefits. The anti-inflammatory and antioxidant effects of melatonin are intertwined and are exerted throughout pregnancy and later during development and aging. Melatonin supplementation during pregnancy can reduce ischemia-induced oxidative damage in the fetal brain, increase offspring survival in inflammatory states, and reduce blood pressure in the adult offspring. In adulthood, disturbances in melatonin production negatively impact the progression of cardiovascular risk factors and promote cardiovascular and neurodegenerative diseases. The most studied cardiovascular effects of melatonin are linked to hypertension and myocardial ischemia/reperfusion injury, while the most promising ones are linked to regaining control of metabolic syndrome components. In addition, there might be an emerging role for melatonin as an adjuvant in treating coronavirus disease 2019 (COVID 19). The present review summarizes and comments on important data regarding the roles exerted by melatonin in homeostasis and oxidative stress and inflammation related pathologies.

show abstract

Section: Melatonin Effects In Neuronal Inflammation and Degeneratimentioning

confidence: 99%

Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cerebrospinal fluid (CSF) concentration of melatonin decreases even at the preclinical stages of AD (104). Circulating melatonin correlates negatively with neuropsychological evaluation in mild cognitive impairment (MCI) and AD patients (105). The relative deficiency of melatonin could be the cause or a consequence of neurodegeneration.…”

Section: Clinical Application Of Melatonin In Admentioning

confidence: 99%

Melatonin: Clinical Perspectives in Neurodegeneration

2019

View full text Add to dashboard Cite

Prevention of neurodegenerative diseases is presently a major goal for our Society and melatonin, an unusual phylogenetically conserved molecule present in all aerobic organisms, merits consideration in this respect. Melatonin combines both chronobiotic and cytoprotective properties. As a chronobiotic, melatonin can modify phase and amplitude of biological rhythms. As a cytoprotective molecule, melatonin reverses the low degree inflammatory damage seen in neurodegenerative disorders and aging. Low levels of melatonin in blood characterizes advancing age. In experimental models of Alzheimer's disease (AD) and Parkinson's disease (PD) the neurodegeneration observed is prevented by melatonin. Melatonin also increased removal of toxic proteins by the brain glymphatic system. A limited number of clinical trials endorse melatonin's potentiality in AD and PD, particularly at an early stage of disease. Calculations derived from animal studies indicate cytoprotective melatonin doses in the 40–100 mg/day range. Hence, controlled studies employing melatonin doses in this range are urgently needed. The off-label use of melatonin is discussed.

show abstract

“…Melatonin is approved by the FDA as a dietary supplement and readily available over the counter, commonly prescribed for treatment of insomnia. Studies report that plasma melatonin levels are significantly decreased in subjects with AD, showing a negative association with cognitive function, and a significant reduction is found even in healthy elderly [93,94,95]. In a rat model of sporadic AD, melatonin was demonstrated to prevent memory loss by attenuating amyloidosis and neurodegeneration [96].…”

Section: Antioxidants Cognitive Decline and Blood-brain Barriermentioning

confidence: 99%

Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective

2016

View full text Add to dashboard Cite

A number of natural and chemical compounds that exert anti-oxidative properties are demonstrated to be beneficial for brain and cognitive function, and some are reported to reduce the risk of dementia. However, the detailed mechanisms by which those anti-oxidative compounds show positive effects on cognition and dementia are still unclear. An emerging body of evidence suggests that the integrity of the cerebrovascular blood-brain barrier (BBB) is centrally involved in the onset and progression of cognitive impairment and dementia. While recent studies revealed that some anti-oxidative agents appear to be protective against the disruption of BBB integrity and structure, few studies considered the neuroprotective effects of antioxidants in the context of cerebrovascular integrity. Therefore, in this review, we examine the mechanistic insights of antioxidants as a pleiotropic agent for cognitive impairment and dementia through a cerebrovascular axis by primarily focusing on the current available data from physiological studies. Conclusively, there is a compelling body of evidence that suggest antioxidants may prevent cognitive decline and dementia by protecting the integrity and function of BBB and, indeed, further studies are needed to directly examine these effects in addition to underlying molecular mechanisms.

show abstract

Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Cited by 32 publications

References 36 publications

Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease

Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease

Melatonin: Clinical Perspectives in Neurodegeneration

Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective

Contact Info

Product

Resources

About